EU Marketing Approval Gap Between Lilly’s Donamemab and Eisai’s Leqembi Could Narrow

The European Medicines Agency is this week set to issue an opinion on whether pan-EU marketing should be granted to Lilly’s Alzheimer’s disease drug donanemab.